Cytokinetics Inc
Ownership
Ownership Structure
Who owns Cytokinetics Inc (CYTK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.5% of the shares are freely tradable; institutional investors hold 118.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 12.61 | 17,523,840 | -35.4 | 03/31/2026 |
| BlackRock Inc | 11.90 | 16,548,011 | +0.9 | 03/31/2026 |
| FMR Inc | 7.71 | 10,723,140 | -16.3 | 03/31/2026 |
| Wellington Management Company LLP | 4.99 | 6,931,770 | -13.5 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 4.20 | 5,843,782 | +0.0 | 03/31/2026 |
| State Street Corp | 4.13 | 5,745,193 | -1.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.95 | 5,488,634 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation | 4.52 | 6,285,983 | +0.0 | 07/31/2026 |
| iShares Core S&P Mid-Cap ETF | 3.42 | 4,754,708 | +0.0 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.11 | 4,329,174 | +0.3 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Blum Robert I | President & CEO | 376,470 | 25,901,136 $ | Sep 14, 2026 | both |
| Malik Fady Ibraham | EVP Research & Development | 153,902 | 10,588,458 $ | Sep 8, 2026 | direct |
| Henderson John T | Director | 78,360 | 5,391,168 $ | Jul 15, 2026 | direct |
| Callos Andrew | EVP, Chief Commercial Officer | 58,555 | 4,028,584 $ | Aug 31, 2026 | direct |
| Wierenga Wendell | Director | 35,563 | 2,446,734 $ | Jul 15, 2026 | direct |
| Wysenski Nancy | Director | 33,992 | 2,338,650 $ | Jul 15, 2026 | direct |
| Harrington Robert Arthur | Director | 21,932 | 1,508,922 $ | Jul 15, 2026 | direct |
| Parshall B Lynne | Director | 10,784 | 741,939 $ | Sep 1, 2026 | direct |
| Kaye Edward M. MD | Director | 10,434 | 717,859 $ | Jul 15, 2026 | direct |
| Landry Robert E | Director | 8,184 | 563,059 $ | Sep 15, 2026 | direct |
| Daly James M | Director | 3,390 | 233,232 $ | Jul 15, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Landry Robert E | Director | Sell | 1,000 | 72.13 | 72,130 |
| Sep 15, 2026 | Blum Robert I | President & CEO | Sell | 97,926 | 69.33 | 6,789,210 |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 97,926 | 0.00 | – |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 1,350 | 0.00 | – |
| Sep 14, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 73.44 | 550,800 |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Sep 11, 2026 | Landry Robert E | Director | Sell | 1,000 | 74.66 | 74,660 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 75.46 | 264,110 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Sep 1, 2026 | Parshall B Lynne | Director | Sell | 5,000 | 71.48 | 357,400 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 10,000 | 70.24 | 702,400 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Other | 10,000 | 23.26 | 232,600 |
| Aug 31, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 70.24 | 526,800 |
| Aug 31, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 75.82 | 265,370 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Aug 10, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 76.76 | 575,700 |
| Aug 10, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | 79.88 | 1,118,320 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Other | 14,000 | 23.26 | 325,640 |
| Jul 27, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 80.87 | 606,525 |
| Jul 27, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 80.59 | 282,065 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Jul 15, 2026 | Wysenski Nancy | Director | Other | 75 | 82.62 | 6,197 |
| Jul 15, 2026 | Wierenga Wendell | Director | Other | 75 | 82.62 | 6,197 |
| Jul 15, 2026 | Kaye Edward M. MD | Director | Other | 151 | 82.62 | 12,476 |
| Jul 15, 2026 | Henderson John T | Director | Other | 272 | 82.62 | 22,473 |
| Jul 15, 2026 | Harrington Robert Arthur | Director | Other | 151 | 82.62 | 12,476 |
| Jul 15, 2026 | Daly James M | Director | Other | 151 | 82.62 | 12,476 |
| Jul 13, 2026 | Blum Robert I | President & CEO | Sell | 7,490 | 82.02 | 614,330 |
| Jul 13, 2026 | Blum Robert I | President & CEO | Other | 7,490 | 10.60 | 79,394 |
| Jul 13, 2026 | Blum Robert I | President & CEO | Sell | 10 | 82.02 | 820 |
| Apr 21, 2026 | Fady Ibraham Malik | EVP | Sell | 3,500 | 65.69 | 229,915 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.